Skip to content
Men Under Microscope – Lifestyle
Author:
Applied Biologics
Applied Biologics Welcomes CMS FDA Coordination for Innovation
September 8, 2026
Applied Biologics Achieves Key Preclinical Milestone in Disease-Modifying Osteoarthritis Gene Therapy Program
September 3, 2026
Applied Biologics Activates First Clinical Site in Phase 3 BIOxHEAL™ Trial
September 1, 2026
Applied Biologics Welcomes CMS’ Continued Commitment to Clinical Evidence in Advanced Wound Care
August 19, 2026
Applied Biologics Announces Acceptance of XWRAP® Translational Research for Presentation at SAWC Fall 2026
August 18, 2026
Applied Biologics Launches National Health System Partnership Initiative
August 12, 2026
CMS Proposed 2027 Medicare Policy Continues Recognition of the FDA’s Section 351 Biologic Pathway
August 10, 2026
Applied Biologics Receives Central IRB Approval for Phase 3 BIOxHEAL™ Clinical Trial
August 5, 2026
Applied Biologics Marks 10 Years of Continuous AATB Accreditation While Initiating Reaccreditation Process
August 4, 2026
Applied Biologics Announces Successful GMP Manufacturing of Initial Clinical Lots of BIOxHEAL™
July 30, 2026
←
Previous Page
1
2
3
4
Next Page
→